EUVIMEDEUVIMED entdecken
Crossref

Ropivacaine and celecoxib-loaded injectable composite hydrogel for improved chronic pain-exacerbated myocardial ischemia-reperfusion injury

Fancan Wu, Wanyou He, Da Song, Zhen Wu, Peng Dai, Xueqin Zheng, Hanbing Wang, Chao Xie

Journal of Controlled Release · 2025-03 · 379 · 266-284

DOI: 10.1016/j.jconrel.2025.01.028 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Controlled Release, 2025-03. Verfasst von Fancan Wu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology, The First People's Hospital of Foshan, Foshan, Guangdong, PR China. Hauptthemen laut MEDLINE: Ropivacaine, Chronic Pain, Hydrogels, Myocardial Reperfusion Injury. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 57 Literaturangaben. Gefördert von: Basic and Applied Basic Research Foundation of Guangdong Province, China Postdoctoral Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic pain is a prevalent condition affecting a significant portion of the global population and is known to be associated with an increased risk of cardiovascular diseases. Despite the clinical relevance, the mechanisms underlying the link between chronic pain and myocardial ischemia-reperfusion (MI/R) injury remain poorly understood. This study aimed to investigate the role of the superior cervical ganglion (SCG) in mediating the effects of chronic pain on MI/R injury and to develop a novel therapeutic strategy. We identified that chronic pain upregulated TNF-α expression and induced hyperactivity in SCG sympathetic neurons, exacerbating MI/R injury. To address this, we engineered an injectable Pluronic/alginate-based composite hydrogel loaded with celecoxib and ropivacaine (celecoxib@Laponite-dopamine-alginate-Pluronic F-127@ropivacaine, CLDAFR). This hydrogel was designed to target the SCG, providing a localized and sustained release of the therapeutic agents, thereby mitigating neuronal inflammation and inhibiting neuronal hyperactivity. The CLDAFR hydrogel demonstrated excellent biocompatibility, heat-sensitive gelation properties, and controlled drug release in vitro. In vivo studies showed that applying CLDAFR effectively reduced MI/R injury in a chronic pain model by suppressing TNF-α expression and SCG neuronal activity. In conclusion, the CLDAFR hydrogel represents a promising therapeutic material for treating chronic pain-exacerbated MI/R injury by precisely targeting the SCG and providing a sustained anti-inflammatory and analgesic effect.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RopivacaineChronic PainHydrogelsMyocardial Reperfusion InjuryCelecoxibAnesthetics, LocalAnimalsMaleAlginatesRats, Sprague-DawleyDelayed-Action PreparationsTumor Necrosis Factor-alphaDrug LiberationPoloxamerMiceRats

Stichwörter der Autor:innen

Chronic painHydrogelMI/R injuryRopivacaineSCG sympathetic neuronTNF-α

Substanzen

RopivacaineHydrogelsCelecoxibAlginatesDelayed-Action PreparationsTumor Necrosis Factor-alphaAnesthetics, LocalPoloxamer

Autor:innen und Institutionen

  • Department of Anesthesiology, The First People's Hospital of Foshan, Foshan, Guangdong, PR China.
  • Department of Biomedical Engineering, Southern University of Science and Technology, Shenzhen, Guangdong, PR China.
  • Department of Critical Care Medicine, Guangdong Second Provincial General Hospital, Jinan University, Guangzhou, Guangdong, PR China.
  • Department of Anesthesiology, The First People's Hospital of Foshan, Foshan, Guangdong, PR China. Electronic address: 1049550363@qq.com.
  • Department of Anesthesiology, The First People's Hospital of Foshan, Foshan, Guangdong, PR China. Electronic address: fswhbing@126.com.
  • Department of Joint and Orthopedics, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, PR China. Electronic address: 380036411@smu.edu.cn.

Förderung

  • Basic and Applied Basic Research Foundation of Guangdong Province
  • China Postdoctoral Science Foundation

Zitieren

APA

Wu, F., He, W., Song, D., Wu, Z., Dai, P., Zheng, X., Wang, H., & Xie, C. (2025). Ropivacaine and celecoxib-loaded injectable composite hydrogel for improved chronic pain-exacerbated myocardial ischemia-reperfusion injury. Journal of Controlled Release, 379, 266-284. https://doi.org/10.1016/j.jconrel.2025.01.028

Vancouver

Wu F, He W, Song D, Wu Z, Dai P, Zheng X, et al. Ropivacaine and celecoxib-loaded injectable composite hydrogel for improved chronic pain-exacerbated myocardial ischemia-reperfusion injury. Journal of Controlled Release. 2025;379:266-284. doi:10.1016/j.jconrel.2025.01.028

BibTeX
@article{Wu2025,
  author = {Wu, Fancan and He, Wanyou and Song, Da and Wu, Zhen and Dai, Peng and Zheng, Xueqin and Wang, Hanbing and Xie, Chao},
  title = {Ropivacaine and celecoxib-loaded injectable composite hydrogel for improved chronic pain-exacerbated myocardial ischemia-reperfusion injury},
  journal = {Journal of Controlled Release},
  year = {2025},
  volume = {379},
  pages = {266--284},
  doi = {10.1016/j.jconrel.2025.01.028}
}
Kostenlos starten →